ZA202407225B - Salt and crystal form of dipeptidyl peptidase inhibitor compound - Google Patents
Salt and crystal form of dipeptidyl peptidase inhibitor compoundInfo
- Publication number
- ZA202407225B ZA202407225B ZA2024/07225A ZA202407225A ZA202407225B ZA 202407225 B ZA202407225 B ZA 202407225B ZA 2024/07225 A ZA2024/07225 A ZA 2024/07225A ZA 202407225 A ZA202407225 A ZA 202407225A ZA 202407225 B ZA202407225 B ZA 202407225B
- Authority
- ZA
- South Africa
- Prior art keywords
- salt
- crystal form
- inhibitor compound
- dipeptidyl peptidase
- peptidase inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210160862 | 2022-02-22 | ||
| PCT/CN2023/077409 WO2023160542A1 (zh) | 2022-02-22 | 2023-02-21 | 二肽基肽酶抑制剂化合物的盐及晶型 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202407225B true ZA202407225B (en) | 2025-12-17 |
Family
ID=87764787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/07225A ZA202407225B (en) | 2022-02-22 | 2024-09-20 | Salt and crystal form of dipeptidyl peptidase inhibitor compound |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250188067A1 (enExample) |
| EP (1) | EP4484414A4 (enExample) |
| JP (1) | JP2025508792A (enExample) |
| KR (1) | KR20240153351A (enExample) |
| CN (1) | CN118660873A (enExample) |
| AU (1) | AU2023225835A1 (enExample) |
| CA (1) | CA3243683A1 (enExample) |
| CL (1) | CL2024002490A1 (enExample) |
| IL (1) | IL314852A (enExample) |
| MX (1) | MX2024010180A (enExample) |
| TW (1) | TW202342466A (enExample) |
| WO (1) | WO2023160542A1 (enExample) |
| ZA (1) | ZA202407225B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4484423A4 (en) * | 2022-02-22 | 2026-01-07 | Haisco Pharmaceuticals Pte Ltd | PROCESS FOR PREPARING A HETEROCYCLIC COMPOUND CONTAINING NITROGEN |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100098683A (ko) * | 2007-12-12 | 2010-09-08 | 아스트라제네카 아베 | 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도 |
| NO2699580T3 (enExample) * | 2014-01-24 | 2018-02-24 | ||
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| RS66302B1 (sr) * | 2020-08-26 | 2025-01-31 | Haisco Pharmaceuticals Pte Ltd | Derivat nitrila koji deluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| AU2022218443B2 (en) * | 2021-02-05 | 2025-03-13 | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | Fused ring derivatives containing 1,4-oxazepane |
-
2023
- 2023-02-21 CA CA3243683A patent/CA3243683A1/en active Pending
- 2023-02-21 AU AU2023225835A patent/AU2023225835A1/en active Pending
- 2023-02-21 IL IL314852A patent/IL314852A/en unknown
- 2023-02-21 US US18/840,826 patent/US20250188067A1/en active Pending
- 2023-02-21 WO PCT/CN2023/077409 patent/WO2023160542A1/zh not_active Ceased
- 2023-02-21 JP JP2024549554A patent/JP2025508792A/ja active Pending
- 2023-02-21 EP EP23759167.2A patent/EP4484414A4/en active Pending
- 2023-02-21 MX MX2024010180A patent/MX2024010180A/es unknown
- 2023-02-21 CN CN202380015239.3A patent/CN118660873A/zh active Pending
- 2023-02-21 KR KR1020247031067A patent/KR20240153351A/ko active Pending
- 2023-02-22 TW TW112106411A patent/TW202342466A/zh unknown
-
2024
- 2024-08-20 CL CL2024002490A patent/CL2024002490A1/es unknown
- 2024-09-20 ZA ZA2024/07225A patent/ZA202407225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342466A (zh) | 2023-11-01 |
| WO2023160542A1 (zh) | 2023-08-31 |
| KR20240153351A (ko) | 2024-10-22 |
| CA3243683A1 (en) | 2025-01-22 |
| MX2024010180A (es) | 2024-08-27 |
| EP4484414A1 (en) | 2025-01-01 |
| JP2025508792A (ja) | 2025-04-10 |
| EP4484414A4 (en) | 2026-01-28 |
| IL314852A (en) | 2024-10-01 |
| US20250188067A1 (en) | 2025-06-12 |
| CL2024002490A1 (es) | 2024-12-13 |
| AU2023225835A1 (en) | 2024-10-03 |
| CN118660873A (zh) | 2024-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553603A1 (en) | Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same | |
| EP4643882A3 (en) | Capsid inhibitors for the prevention of hiv | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| NZ616806A (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| WO2019178191A8 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
| MX2025000291A (es) | Compuesto heterocíclico capaz de inhibir prmt5mta y uso del mismo | |
| WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
| MX2021011823A (es) | Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MXPA05012675A (es) | Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa. | |
| CL2024002490A1 (es) | Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa | |
| AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
| TW200626553A (en) | Novel compounds | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| HRP20050103A2 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
| MX2010007426A (es) | Composiciones farmaceuticas para tratar trastorno del higado graso. | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| SG149001A1 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | |
| WO2006042478A8 (fr) | Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation |